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Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting
the epidermal growth factor receptor (EGFR), and both are widely used in combination
with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic
colorectal cancer. Although often considered interchangeable, the two antibodies have
different molecular structures and can behave differently in clinically relevant ways. More
specifically, as an immunoglobulin (Ig) G1 isotype mAb, cetuximab can elicit immune
functions such as antibody-dependent cell-mediated cytotoxicity involving natural killer
cells, T-cell recruitment to the tumor, and T-cell priming via dendritic cell maturation.
Panitumumab, an IgG2 isotype mAb, does not possess these immune functions.
Furthermore, the two antibodies have different binding sites on the EGFR, as evidenced
by mutations on the extracellular domain that can confer resistance to one of the
two therapeutics or to both. We consider a comparison of the properties of these
two antibodies to represent a gap in the literature. We therefore compiled a detailed,
evidence-based educational review of the known molecular, clinical, and functional
differences between the two antibodies and concluded that they are distinct therapeutic
agents that should be considered individually during treatment planning. Available data
for one agent can only partly be extrapolated to the other. Looking to the future, the
known immune activity of cetuximab may provide a rationale for this antibody as a
combination partner with investigational chemotherapy plus immunotherapy regimens
for colorectal cancer.
Keywords: colorectal cancer, cetuximab, panitumumab, FOLFOX, FOLFIRI, antibody-dependent cell-mediated
cytotoxicity
INTRODUCTION
The advent of targetedmonoclonal antibodies (mAbs) brought a revolution in the field of oncology.
With increased specificity, longer half-lives, and more predictable overall pharmacokinetic and
pharmacodynamic behaviors than their small-molecule inhibitor counterparts, mAbs have become
key components of standard-of-care treatments for multiple indications. Inevitably, sometimes
several approved mAbs against the same target are available, requiring physicians to perform
detailed research to understand which mAb is the optimal therapeutic agent for a given patient.
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In fact, more than half of the approved targeted mAbs in
oncology (excluding the new wave of checkpoint inhibitors)
are clustered around 5 targets: the epidermal growth factor
receptor (EGFR), the human epidermal growth factor receptor 2
(HER2), tumor necrosis factor α, CD20, and vascular endothelial
growth factor (VEGF) (1). Indeed, among treatment options
for metastatic colorectal cancer (mCRC), in particular, are
two anti-EGFR mAbs, cetuximab and panitumumab, currently
indicated for the same subgroup of patients, those with RAS
wild-type (wt) metastatic disease (2, 3). Approximately 40% of
patients with CRC will eventually develop metastatic disease
(4); per international guidelines, the majority of these patients
should undergo RAS testing for suitability for an anti-EGFR
mAb in combination with oxaliplatin- or irinotecan-based
chemotherapy. Thus, clinicians must choose between prescribing
cetuximab and panitumumab regularly.
In 2004, cetuximab was approved by both the US FDA
and the EMA for use in EGFR-expressing (K)RAS-unselected
chemorefractory mCRC. Panitumumab was approved by the
US FDA for use in the same patient population in 2006.
In 2007, the EMA rejected the use of panitumumab in an
unselected chemorefractory population, but approved the use
of panitumumab in a restricted population of KRAS exon 2 wt
mCRC, and imposed a similar restriction on use of cetuximab
in 2008. By 2009, the FDA followed the EMA by restricting use
of either anti-EGFR agent to KRAS exon 2 wt chemorefractory
mCRC patients.
In the first-line setting, panitumumab + CT was approved by
the EMA in 2011, based on positive results from the randomized
phase 3 PRIME trial. In 2012, cetuximab + CT was approved by
the FDA following the phase 3 CRYSTAL trial. In 2013, extended
RAS testing was required by the FDA and EMA for predicting
response to anti-EGFR agents (5).
According to the EU SmPC, cetuximab is currently indicated
for EGFR-expressing RAS wt mCRC as a monotherapy
in patients who have failed oxaliplatin- and irinotecan-
based therapy and who are intolerant to irinotecan, in
combination with irinotecan-based therapy in any line, and
in combination with FOLFOX in first-line. Cetuximab is
also indicated for use in SCCHN, both in locally advanced
disease (in combination with radiation therapy) and in
recurrent/metastatic disease (in combination with platinum-
based chemotherapy). Panitumumab is indicated for RAS wt
mCRC as a monotherapy after failure of fluoropyrimidine-,
oxaliplatin-, and irinotecan-containing chemotherapy regimens,
in combination with FOLFOX or FOLFIRI in first-line, and in
combination with FOLFIRI in second-line mCRC (6, 7).
To date, >480,000 patients with mCRC have received
cetuximab-based therapy worldwide, and>240,000 patients with
mCRC have been treated with panitumumab-containing therapy
(8, 9). Although these twomAbs are considered to be very similar,
important biological, molecular, and practical differences exist
between them. Thus, there are uncertainties regarding whether
they can be considered equivalent and whether it is prudent to
ascribe conclusions gleaned from a study of one agent to the
other and to pool data on the two in meta-analyses. In this article,
we summarize and discuss these differences, primarily within
the context of mCRC, but we also describe their differential
activity in the treatment of squamous cell carcinomas of the head
and neck (SCCHN). We then relate how these differences could
impact the potential for anti-EGFR mAbs to be combined with
emerging immunotherapies. The goal of this review is to provide
a comprehensive discussion of the available data on the twomAbs
and to highlight how they are distinct therapeutic agents with
individual, clinically relevant properties.
MODE OF ACTION AGAINST EGFR
Dysregulation in the EGFR signaling pathway has long been
associated with pro-oncogenic activities such as increased cell
proliferation, reduced apoptosis, and increased angiogenesis
and metastatic tendencies (1, 4, 10). The EGFR is activated
when one of its many ligands (including the epidermal growth
factor [EGF], transforming growth factor α, amphiregulin, or
epiregulin) binds the receptor’s extracellular domain, resulting
in receptor dimerization, conformational change, and tyrosine
autophosphorylation (4, 10, 11). Upon receptor binding,
downstream signaling cascades including the MAPK/ERK
(mitogen-activated protein kinase/extracellular signal-regulated
kinase), JAK/STAT (Janus kinase/signal transducers and
activators of transcription), and PI3K/Akt (phosphoinositide
3-kinase/protein kinase B) pathways become active. Constitutive
activation of these pathways can lead to cancer cell survival and
proliferation (1, 4, 5).
Cetuximab and panitumumab both function by binding to the
extracellular domain III of the EGFR, thereby preventing ligand
binding and locking the EGFR in the autoinhibitory monomeric
conformation (1, 4, 11). The antibody-receptor construct is
then internalized, ubiquitinated, and either degraded or recycled.
This turnover is regulated by the ubiquitin proteasome system
(12, 13). Briefly, after activation of the receptor tyrosine
kinase through ligand binding and dimerization, the activated
receptor is internalized by clathrin-dependent endocytosis and
ubiquitinated. This process terminates the tyrosine kinase activity
of activated EGFR and regulates the number of receptors
expressed on the cell surface. The final step of degradation is
performed by the proteasome; however, ubiquitinated receptors
can be deubiquitinated by deubiquitinating enzymes and then
recycled back to the cell membrane (12). Receptor ubiquitination
has been identified as a mechanism of resistance to anti-EGFR
therapy (12).
Between 60 and 80% of colorectal tumors overexpress the
EGFR; although this characteristic was historically thought to
be predictive of response to cetuximab and panitumumab, in
more recent years this notion has not held up in practice (1,
4, 14). Alternative explanations for the efficacy of cetuximab
and panitumumab in colorectal tumors regardless of EGFR
overexpression status focus on the ligands to EGFR and potential
dysregulation of the amount of ligands produced and released
into the extracellular space (5). Indeed, both cetuximab and
panitumumab compete with EGF for its binding site on EGFR.
Mutational studies have demonstrated that the two mAbs have
different binding sites on EGFR, but the binding epitopes are in
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close physical proximity and have some key residues in common
(15) (Table 1). Panitumumab’s binding epitope includes EGFR
residues P349, P362, D355, F412, and I438, all of which are
individually necessary for≥50% binding affinity (15). In contrast,
binding residues on EGFR critical for cetuximab binding are
Q384, Q408, H409, K443, K465, I467, and S468, as well as F352,
D355, and P387 (15). D355 is likely a source of competition
between themAbs and EGF because it is within the binding site of
all three molecules (15). Notably, panitumumab’s binding epitope
overlaps with the EGF binding site in two locations (D355 and
K443), whereas cetuximab overlaps with EGF’s binding site in 5
locations (D355, Q408, H409, K443, and S468).
Furthermore, cetuximab and panitumumab have different
binding affinities for EGFR, with dissociation constants (KD) of
0.39 nM vs. 0.05 nM, respectively (4). Cetuximab binds EGFR
with∼2-fold greater affinity than EGF (16). Panitumumab binds
EGFR with an ∼8-fold greater affinity than that of cetuximab.
However, it is unclear whether this characteristic is favorable.
From one standpoint, a higher affinity for EGFR should translate
into a greater proportion of mAb-bound EGFR; conversely,
however, studies have observed that a KD between 1 and 10 nM is
optimal for anti-EGFR mAb tumor targeting, accumulation, and
retention (11). Although the KD of cetuximab is closer, neither
mAb is within the optimal range. Cetuximab and panitumumab
administration schedules are very different from each other
(Table 1). Cetuximab is administered based on body surface area,
and is usually given as a 400-mg/m2 initial dose by a 120-min
intravenous (IV) infusion, followed by a weekly dose of 250
mg/m2 by 60-min IV infusion (6). However, Q2W doses of 500
mg/m2 have been investigated; this dosing schedule is frequently
used, and is recommended based on NCCN guidelines but not
approved by regulatory authorities (3). Maintenance cetuximab
can be administered on the same weekly or Q2W schedule (17)
and treatment with cetuximab is recommended to be given until
progression of disease (6). Indeed, in pharmacokinetic studies,
a 250-mg/m2 weekly cetuximab dose has a mean half-life of
4.19 days and a minimum recorded mean concentration of
49.6µg/mL (17). By comparison, panitumumab is administered
by weight at a dose of 6 mg/kg every 2 weeks; a 60-min infusion
time is recommended for total doses ≤ 1,000mg, and a 90-min
infusion time is recommended for total doses > 1,000mg (7).
At this administration schedule, panitumumab’s mean half-life is
7.5 days, with a minimum recorded mean serum concentration
of 39µg/mL (18). Studies have indicated that it takes 3
infusions of panitumumab to reach steady state (19), although
similar information has not been published for cetuximab.
Overall, administration of cetuximab and panitumumab per
their standard schedules results in comparable pharmacokinetic
behaviors and overall drug exposures. One final structural
difference between the two mAbs is found in their respective
backbones. Panitumumab is a human mAb and cetuximab is
a mouse/human chimeric mAb. Although this distinction can
sometimes lead to differences in the rates of infusion-related
reactions between the two agents, these can be managed with the
appropriate pre-medication prior to infusion.
MOLECULAR STRUCTURE AND
ASSOCIATED IMMUNE ACTIVITY
One of the most hotly debated topics is the functional
implication of the differing immunoglobulin (Ig) G subtypes
of cetuximab and panitumumab—namely, that cetuximab is
an IgG1 isotype mAb, whereas panitumumab has the IgG2
backbone (Figure 1, Table 1) (4, 38). The two Ig isotypes differ
in their ability to mobilize innate and adaptive immune cells
TABLE 1 | Basic comparison of cetuximab and panitumumab.
Variable Cetuximab Panitumumab
Approved indications
(acc.to EU label)
mCRC:
• in combination with irinotecan-based chemotherapy
• in first-line in combination with FOLFOX
• as a single agent in patients who have failed
oxaliplatin- and irinotecan-based therapy and who are
intolerant to irinotecan
SCCHN:
• in combination with radiation therapy for LA SCCHN
• in combination with platinum-based chemotherapy for
R/M SCCHN
mCRC:
• in first-line in combination with FOLFOX or FOLFIRI
• in second-line in combination with FOLFIRI for patients
who have received first-line, fluoropyrimidine-based
chemotherapy (excluding irinotecan)
• as monotherapy after failure of fluoropyrimidine-,
oxaliplatin-, and irinotecan-containing
chemotherapy regimens
IgG isotype IgG1 IgG2
Fc Chimeric (mouse/human) Human
EGFR binding sites in the
EGF-binding pocket
D355, Q408, H409, K443, S468 D355, K443
KD 0.39 nM 0.050 nM
Immune activity NK cell–driven ADCC, CDC Monocyte/neutrophil-driven ADCC
Registered
dose/posology
400 mg/m2 initial dose as a 120-min IV infusion,
followed by 250 mg/m2 weekly as a 60-min IV infusion
6 mg/kg every 2 weeks as an IV infusion over 60min
(≤1,000mg) or 90min (>1,000mg)
ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-mediated cytotoxicity; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; FOLFOX, oxaliplatin,
leucovorin, and fluorouracil; Ig, immunoglobulin; IV, intravenous; KD, dissociation constant; LA, locally advanced; NK, natural killer; R/M, recurrent and/or metastatic; SCCHN, squamous
cell carcinoma of the head and neck.
Frontiers in Oncology | www.frontiersin.org 3 September 2019 | Volume 9 | Article 849
García-Foncillas et al. Two Distinct Anti-EGFRs: Cetuximab and Panitumumab
FIGURE 1 | Overview of differences in immune activation with cetuximab and panitumumab. Shown in orange: sites of activation by both anti–epidermal growth
factor receptor (EGFR) monoclonal antibodies (mAbs). Both anti-EGFR mAbs neutralize the cross talk between the cancer cells and M2 monocytes and
cancer-associated fibroblasts (CAFs) by neutralization of EGFR ligands. On the basis that cetuximab and panitumumab may have identical effects, from a mechanistic
point of view, both antibodies reduce vascular endothelial growth factor (VEGF) production (20, 21). Cetuximab can upregulate calreticulin (CRT), heat shock protein
(HSP) 90, and major histocompatibility complex (MHC) (22, 23), which may be theoretically upregulated by panitumumab (not reported). Shown in blue: sites
activated by cetuximab. Natural killer (NK) cells are activated by their binding to the cetuximab loaded onto EGFR (22, 24, 25). The released interferon γ (IFN-γ)
activates dendritic cells (DCs), which further activate the NK cells (26). Cetuximab-induced antibody-dependent cell-mediated cytotoxicity (ADCC),
complement-dependent cell-mediated cytotoxicity (CDCC), complement-mediated cytotoxicity (CDC) (27–30), and immunogenic death (31) release tumor antigens,
which are captured by the activated DC cells, to be presented to T cells (thus activating them). IFN-γ upregulates programmed cell death 1 ligand 1 (PD-L1) on tumor
cells and activates macrophages to release chemoattraction substances for NK cells and T cells (25). Inhibition of the angiogenic factors VEGF, interleukin (IL) 8, and
fibroblast growth factor (FGF) can be downregulated by both cetuximab and possibly by panitumumab (20, 21). Inhibition of these factors upregulates key homing
adhesion molecules for the immune cells (intercellular adhesion molecule 1 [ICAM-1] and vascular cell adhesion protein 1 [VCAM-1]) (32, 33) and downregulates Fas
antigen ligand (FasL) expression (34), which would be lethal for T cells. These effects enable the safe transmigration of T cells and NK cells into the tumor
microenvironment (35). The T cells activated by DCs loaded with tumor cell antigens are then ready to attack the tumor cells. Shown in black: Immune suppressive
mechanisms/prevention of the successful attack of activated cytotoxic T cells on tumor cells. These mechanisms include checkpoint inhibitory factors (programmed
cell death 1 protein [PD-1], PD-L1, cytotoxic T-lymphocyte protein 4 [CTLA-4]) and TGF-β generated by tumor-associated cells (25). Notably, irinotecan and fluorouracil
(5-FU) can eliminate tumor protective cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), from the tumor microenvironment
(36, 37), reducing their immune suppressive effects and thus potentially facilitating the T-cell attack. bFGF, basic fibroblast growth factor; EREG, epiregulin; HB-EGF,
heparin-binding EGF-like growth factor; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; TGF-β, transforming growth factor β.
against tumor cells (Figure 1, Table 2). For example, it has
been demonstrated in preclinical models and ex vivo studies
that target-bound cetuximab and other IgG1 isotype mAbs
(e.g., rituximab, necitumumab, trastuzumab) stimulate natural
killer (NK) cell–driven cytotoxicity against tumor cells coated
in mAbs via the interaction of the constant region and the
CD16 receptor on NK cells (38, 44–47). This antibody-dependent
cell-mediated cytotoxicity (ADCC) is specifically carried out
by NK cells of the innate immune system against tumor cells,
resulting in antigen release into the intratumoral space (16).
By secreting cytokines and interferon γ, active NK cells are
further able to stimulate dendritic cell (DC) maturation and DC-
NK cell cross talk (24, 27, 38) and use increased expression
of CD137 to recruit anti-EGFR CD8+ cytotoxic T cells to the
intratumoral space for additional cell-killing activity (40, 41,
48). In turn, mature DCs can mobilize a number of additional
immunogenic processes, including antigen presentation to
cytotoxic T cells and further activation of NK cells (24, 27, 38, 48).
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TABLE 2 | Cetuximab and panitumumab: differences in immune activation.
Variable Cetuximab Panitumumab
Cetuximab-related immune cytotoxicity
ADCC Yes (27–30) Activates neutrophil-mediated
ADCC and monocytes (1, 27)
CDCC Yes (29) –
CDC Yes (29) –
Effects on microenvironment cytokines and MMP
Downregulation of IL-8 Yes (20, 21) Probably
Downregulation of VEGF Yes (20, 21) Yesa (20, 21)
Downregulation of bFGF Yes (20, 21) Probably
Downregulation of MMP-9 Yes (39) Probably
Effects on NK cells
NK cell chemoattraction Yes (35) No
Increased NK cell infiltration Yes (31, 35) No
NK cell activation and HLA
expression
Good (22, 24, 25) No (24)
NK cell activation (CD137
upregulation)
Good (40, 41) Less (27)
IFN-γ induction by NK cells Yes (24) No (24)
Increase in TAP-1 in NK cells Yes (24) No (24)
Cross-presentation of tumor
antigens by NK cells
Significantly better (27) No (27)
Effects on DCS
DC maturation (increase in
CD80, CD83, CD86, HLA-DR)
Good (23, 24) No (24)
DC activation Good (23, 24) No (24)
Increase in TAP-1 and TAP-2 in
DCs (activation)
Yes (24, 42) No (24)
DC upregulation of MHC class I
(MICA)
Yes (24) Not reported
Enhanced reciprocal DC-NK cell
activation/cross talk
Yes (24, 27) No or significantly reduced
(24, 27)
Increased DC phagocytosis Yes (23) Not reported
Increase in efficiency of antigen
cross-presentation by DCs to T
cells
Good (24) Weak (24)
Effects on macrophages
Macrophage activation Yes (indirect) (25) Not expected
Effect on cytotoxic T cells
Increased T-cell chemoattraction Yes (35) Not expected
Increased T-cell infiltration Yes (35) Not expected
T-cell activation Yes (24) Significantly less than cetuximab
(24)
Immune priming effects on tumor cells
Upregulation of MHC class I Yes (24) Possibly
Immunogenic cell death Yes (31) Not reported
Immune responses induced by cetuximab + irinotecan combination
Effects on microenvironment cytokines
IL-2 increase Yes (26) Not reported
IFN-γ increase Yes (26) Not reported
IL-12 increase Yes (26) Not reported
IL-18 increase Yes (26) Not reported
IL-4 decrease Yes (26) Not reported
(Continued)
Frontiers in Oncology | www.frontiersin.org 5 September 2019 | Volume 9 | Article 849
García-Foncillas et al. Two Distinct Anti-EGFRs: Cetuximab and Panitumumab
TABLE 2 | Continued
Variable Cetuximab Panitumumab
Effects on immune cells in the TME
Increase in circulating NK cells Yes (43) Not reported
Increase in circulating DCs Yes (43) Not reported
DC activation Yes (23) Not reported
Increased DC phagocytosis and
trogocytosis
Yes (23) Not reported
Increase in activated T cells Yes (43) Not reported
Increase in central memory cells Yes (43) Not reported
Treg elimination Yes (26) Not reported
Immune effects on tumor cells
Increase in tumor cell
immunogenicity by upregulating
calreticulin, HSP 90
Yes (23) Not reported
Increased immunogenic death Yes (31) Not reported
Improved immune “contexture” Yes (26) Not reported
aOn the basis that cetuximab and panitumumab may have identical effects, from a mechanistic point of view.
ADCC, antibody-dependent cell-mediated cytotoxicity; bFGF, basic fibroblast growth factor; CAF, cancer-associated fibroblasts; CDC, complement-mediated cytotoxicity; CDCC,
complement-dependent cell-mediated cytotoxicity; DC, dendritic cell; HLA, human leukocyte antigen; HSP 90, heat shock protein 90; IFN-γ , interferon γ ; IL, interleukin; MDSC,
myeloid-derived suppressor cell; MHC, major histocompatibility complex; MICA, MHC class I polypeptide-related sequence A; MMP, matrix metalloproteinase; NK, natural killer; TAP,
transporter associated with antigen processing; TME, tumor microenvironment; Treg, regulatory T cell; VEGF, vascular endothelial growth factor.
Collectively, NK cell–mediated ADCC and other immunogenic
activity of IgG1 mAbs is thought to contribute to their antitumor
activity, provided that sufficient target is available for the mAbs
to dually bind to CD16 and their intended epitope (46, 49–
51). This sequence of immune events initiated by cetuximab
can be viewed as a chain reaction reminding of a domino effect
(Figure 1). Furthermore, some clinical evidence has suggested
that patients with higher baseline ADCC activity or specific
CD16 polymorphisms that increase NK cell–binding affinity
might be likelier to experience favorable outcomes with IgG1-
based therapy (28, 52–55). By contrast, the Fc region of the
IgG2 backbone of panitumumab has very low binding affinity for
CD16; thus, panitumumab is unable to induce NK cell–driven
ADCC or cytotoxic T-cell tumor infiltration (16, 48), although
evidence suggests that panitumumab instead induces some
immunostimulatory action via neutrophil-driven ADCC and
monocytes (1, 27). However, its immunogenic properties are not
considered to actively contribute to panitumumab’s antitumor
activity (47, 48). A final difference in the immunostimulatory
capabilities of IgG1 and IgG2 mAbs concerns the C1 complex
of complement, which can be induced by clusters (hexamers) of
IgG1 mAbs but has not been shown to be induced to the same
degree by IgG2 mAbs (47, 56, 57).
BIOMARKERS OF RESPONSE, TARGET
POPULATIONS, AND THERAPEUTIC
RESISTANCE
Colorectal cancer is a highly heterogeneous disease (5),
characterized by predictive and prognostic mutations (58, 59)
as well as a tendency to undergo clonal selection under drug
pressure and develop acquired resistance to certain therapies
(60–62). For example, as recommended by the international
guidelines, both cetuximab and panitumumab are suitable only
for patients with RAS wt colorectal tumors, with genetic analysis
of KRAS exon 2 (codons 12, 13), exon 3 (codons 59, 61), exon
4 (codons 117, 146) and NRAS exon 2 (codons 12, 13), exon
3 (codons 59, 61), and exon 4 (codons 117, 146) (“RAS wt”)
(2, 3, 5, 63). Although several early retrospective RAS analyses
(58, 64) provided evidence supporting testing beyondKRAS exon
2 (i.e., extended RAS analysis), the retrospective analysis of the
PRIME study was the first phase 3 analysis to support refinement
of the patient population by RAS status and the need for extended
RAS analyses. In PRIME, panitumumab in combination with
FOLFOX4was shown to have greater benefit in aRASwt-targeted
patient population rather than in a patient population identified
as KRAS wt, compared with FOLFOX4 alone (65). Additional
post hoc analyses of several phase 3 trials involving cetuximab
have also demonstrated improved responses and survival with
cetuximab-based therapy with FOLFOX or FOLFIRI in patients
with RAS wt mCRC compared with patients with KRAS wt
tumors (66–68). Results from the TAILOR trial, the first phase
3 study to prospectively recruit a RAS wt patient population for
first-line treatment of mCRC with cetuximab plus chemotherapy
(specifically, FOLFOX), further confirmed the survival benefit
with cetuximab-based treatment in RAS wt mCRC (69). Finally,
KRAS amplification, although much rarer than and nearly
always mutually exclusive with KRAS mutations (amplification
is present in ∼1–2% of cases of mCRC) (5), has been shown
to confer resistance to cetuximab and panitumumab and is
considered an emerging biomarker by current guidelines (2).
In addition to mutations existing in the predominant cell
population of the tumor before treatment, overall resistance
to therapy can arise during anti-EGFR therapy, as the drug
can inhibit growth of sensitive clones, thereby allowing for
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expansion of initially rare RAS-mutant clones (10, 62). Indeed,
there is preclinical and clinical evidence available demonstrating
that RAS wt tumors can “switch” to RAS mutant after anti-
EGFR treatment (with either cetuximab or panitumumab) (70),
likely because of a significant reduction of the wt clone and
an expansion of mutated clones. Finally, recent studies have
suggested the possibility of a restoration of responsiveness
to cetuximab after the development of resistance to previous
cetuximab treatment (71, 72). The prospective CRICKET study,
which evaluated third-line re-treatment with cetuximab plus
irinotecan after an initial response followed by progression while
patients had received the same regimen in the first line, showed
that RAS wt status in circulating tumor DNA before start of
third-line therapy was significantly associated with prolonged
progression-free survival (PFS) compared with a RAS mutated
status (73).
Resistance to anti-EGFR therapy can also be conferred
through extracellular domain mutations in the EGFR itself,
which have been observed in only EGFR therapy–experienced
patients, suggesting that these mutations arise specifically as
a mechanism of acquired resistance (13, 60, 74–76). Notably,
different mutations in the extracellular domain can dictate
resistance only to cetuximab, only to panitumumab, or to
both mAbs, owing to their differential binding sites (15). For
example, the S492R and S468R mutations in the extracellular
domain of the EGFR confer resistance only to cetuximab
(13, 75), whereas the G465R mutation that arises in 1 of
every 6 patients who receive panitumumab confers resistance
to both mAbs (77). Such observations may have implications
for planning treatment sequencing, treatment continuation,
and maintenance therapy designed to maximize the number
of efficacious lines of therapy and the likelihood of response
at each stage.
CLINICAL IMPACT OF CETUXIMAB AND
PANITUMUMAB IN COLORECTAL CANCER
Over the last two decades, cetuximab and panitumumab have
been evaluated for efficacy and safety in mCRC in many clinical
trials. With approximately half a million patients treated with
cetuximab, and close to a quarter of a million treated with
panitumumab, the clinical impact of these two mAbs on the
disease has been substantial. Currently, the median overall
survival (OS) in patients who present with RAS wt metastatic
disease is usually ≥ 30 months, with hazard ratios (HRs)
for survival with first-line cetuximab-based therapy of 0.763
in combination with FOLFOX vs. FOLFOX alone, 0.69 in
combination with FOLFIRI vs. FOLFIRI alone, and 0.70 to 0.90 in
combination with either doublet chemotherapy vs. bevacizumab
plus doublet chemotherapy, according to phase 3 trials (66, 67,
69, 78). Although panitumumab has not been extensively studied
in combination with FOLFIRI chemotherapy in the first-line
setting, first-line panitumumab plus FOLFOX vs. FOLFOX alone
yielded anHR for survival of 0.78 in a retrospective analysis of the
RAS wt population of the phase 3 PRIME trial (65). Additionally,
a retrospective analysis of the phase 2 PEAK trial yielded an
HR for survival of 0.63 with panitumumab plus FOLFOX vs.
bevacizumab plus FOLFOX in the population with RAS wt
disease; however, patient numbers were much lower in this phase
2 study than in the analogous cetuximab phase 3 CALGB/SWOG
80405 and FIRE-3 trials (63, 67, 78).
A full summary of the available first-line data for cetuximab
and panitumumab in combination with chemotherapy is
presented in Table 3. Notably, however, while cetuximab
has been shown to pair well with FOLFIRI, FOLFOX, and
FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan)
chemotherapy backbones in multiple randomized studies (66,
67, 78, 85, 86, 89), almost all available data for panitumumab in
the first-line RAS wt setting are in combination with FOLFOX
and include only 1 phase 3 and 1 phase 2 study. Evidence for
panitumumab plus FOLFIRI in mCRC comes from two studies.
The first was a phase 2, single-arm study of panitumumab +
FOLFIRI in first-line mCRC, which showed favorable efficacy
of the combination in KRAS wt vs. KRAS mt mCRC (90). The
second study was the phase 3 20050181 trial, which administered
this combination in the second-line setting in patients with
KRAS wt mCRC. The phase 3 second-line study reported a
significant but modest improvement in PFS compared with
FOLFIRI alone (median, 6.7 vs. 4.9 months; HR, 0.82), a trend
toward improvement in OS (median, 14.5 vs. 12.5 months;
HR, 0.92), and a significant improvement in objective response
rate (ORR; 36 vs. 10%) (91). Recently, the phase 2 Gruppo
Oncologico del Nord Ovest (GONO) and VOLFI trials provided
published evidence for the first-line panitumumab combination
with FOLFOXIRI in patients (N = 37 and N = 96, respectively)
with non–liver-limited mCRC (88, 92).
In recent years, primary tumor location has gained
importance as another characteristic of mCRC that impacts
patient prognosis and treatment decision making. Primary
tumor location (right vs. left, or proximal vs. distal, respectively)
has been demonstrated to have significant implications
for patient survival and response to available therapies
(93). Specifically, patients diagnosed with left-sided tumors
have appeared to have better responses with anti-EGFR
therapy than with anti-VEGF therapy, with the bulk of
tumor location subgroup analysis evidence coming from
the available cetuximab-based phase 3 trials. In contrast,
patients with right-sided tumors have appeared to derive less
benefit from therapy in general (80, 94). In the populations
of patients with RAS wt left-sided primary tumors in the
CALGB/SWOG 80405 and FIRE-3 trials, the median OS
approached 40 months with cetuximab plus chemotherapy
(FOLFIRI or FOLFOX in CALGB/SWOG 80405 and FOLFIRI
in FIRE-3) (80, 94). Indeed, a small retrospective study by
Sagawa et al. demonstrated a median OS of over 50 months
with cetuximab-based treatment in patients with RAS wt
left-sided tumors (95). Furthermore, improvements in OS
with cetuximab-based treatment were statistically significant
compared with bevacizumab-based treatment in the population
with RAS wt left-sided tumors (80, 94, 95). Efficacy data for
first-line panitumumab- vs. bevacizumab-based treatment in
RAS wt left-sided mCRC are available only from the phase 2
PEAK study, in which OS trended toward improvement with
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TABLE 3 | Clinical impact of cetuximab and panitumumab in RAS wt mCRC*.
Study Patients, n Treatment regimen Median PFS, months Median OS, months ORR, %
CALGB/SWOG
(78–80)
270 vs. 256 Cetuximab +
FOLFOX/FOLFIRI vs.
bevacizumab +
FOLFOX/FOLFIRI
11.4 vs. 11.3 (HR, 1.1 [95%
CI, 0.9–1.3]; P = 0.31)
32.0 vs. 31.2 (HR, 0.9 [95%
CI, 0.7–1.1]; P = 0.40)
68.8 vs. 56.0 (P < 0.01)
FIRE-3 (67) 199 vs. 201 Cetuximab + FOLFIRI vs.
bevacizumab + FOLFIRI
10.3 vs. 10.2 (HR, 0.97
[95% CI 0.78–1.20])
33.1 vs. 25.0 (HR, 0.70
[95% CI, 0.54–0.90])
65.3 vs. 58.7 (OR, 1.33
[95% CI, 0.88–1.99])
CRYSTAL (66) 178 vs. 189 Cetuximab + FOLFIRI vs.
FOLFIRI
11.4 vs. 8.4 (HR, 0.56 [95%
CI, 0.41–0.76]; P < 0.001)
28.4 vs. 20.2 (HR, 0.69
[95% CI, 0.54–0.88]; P =
0.0024)
66.3 vs. 38.6 (OR, 3.11
[95% CI, 2.03–4.78]; P <
0.001)
COIN (81) 362 vs. 367 Cetuximab + oxaliplatin +
fluoropyrimidine vs.
oxaliplatin +
fluoropyrimidine
8.6 vs. 8.6 (HR, 0.96 [95%
CI, 0.82–1.12]; P = 0.60)
17.0 vs. 17.9 (HR, 1.04
[95% CI, 0.87–1.23]; P =
0.67)
64 vs. 57 (OR, 1.35 [95%
CI, 1.00–1.82]; P = 0.049)
OPUS (82, 83) 38 vs. 49 Cetuximab + FOLFOX vs.
FOLFOX
12.0 vs. 5.8 (HR, 0.53 [95%
CI, 0.27–1.04]; P = 0.0615)
19.8 vs. 17.8 (HR, 0.94
[95% CI, 0.56–1.56]; P =
0.80)
58 vs. 29 (OR, 3.33 [95%
CI, 1.36–8.17]; P = 0.0084)
TAILOR (69) 193 vs. 200 Cetuximab + FOLFOX vs.
FOLFOX
9.2 vs. 7.4 (HR, 0.69 [95%
CI, 0.54–0.89]; P = 0.004)
20.7 vs. 17.8 (HR, 0.76
[95% CI, 0.61–0.96]; P =
0.02)
61.1 vs. 39.5 (OR, 2.41
[95% CI, 1.61–3.61]; P <
0.001)
BELIEF (84) 45 vs. 48 Cetuximab +
FOLFOX/FOLFIRI vs.
FOLFOX/FOLFIRI
9.8 vs. 5.3 (HR, 0.52 [95%
CI, 0.33–0.81]; P = 0.002)
35.1 vs. 21.7 (HR, 0.44;
[95% CI, 0.23–0.83]; P =
0.009)
62.2 vs. 29.2
MACBETH
(85, 86)
59 vs. 57 Cetuximab + mFOLFOXIRI
(with cetuximab
maintenance) vs. cetuximab
+ FOLFOXIRI (with
bevacizumab maintenance)
10.1 vs. 9.3 (HR, 0.83 [95%
CI, 0.57–1.21])
33.2 vs. 32.2 (HR, 0.92
[95% CI, 0.57–1.47])
71.6% in the entire cohort
PEAK (63) 88 vs. 82 Panitumumab + FOLFOX
vs. bevacizumab + FOLFOX
13.0 vs. 9.5 (HR, 0.65 [95%
CI, 0.44–0.96]; P = 0.029)
41.3 vs. 28.9 (HR, 0.63
[95% CI, 0.39–1.02]; P =
0.058)
63.6 vs. 60.5
PRIME (65) 259 vs. 253 Panitumumab + FOLFOX
vs. FOLFOX
10.1 vs. 7.9 (HR, 0.72 [95%
CI, 0.58–0.90]; P = 0.004)
26.0 vs. 20.2 (HR, 0.78
[95% CI, 0.62–0.99]; P =
0.04)
Not reported for the RAS wt
population
PLANET (87) 27 vs. 26 Panitumumab + FOLFOX
vs. panitumumab + FOLFIRI
13 vs. 15 (HR, 0.7, 95% CI,
0.4–1.3; P = 0.307)
39 vs. 49 (HR, 0.9 [95% CI,
0.4–1.9]; P = 0.824)
78 vs. 73 (P = 0.691)
VOLFI (88) 63 vs. 33 Panitumumab +
mFOLFOXIRI vs. FOLFOXIRI
10.8 vs. 10.5 (HR, 1.11,
95% CI, 0.69–1.75; P =
0.6634)
NA 85.7% vs. 60.6% (OR, 3.90
[95% CI, 1.44–10.52]; P =
0.0096)
CALGB, Cancer and Leukemia Group B; CRYSTAL, Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer; FIRE-3, FOLFIRI Plus Cetuximab vs.
FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colorectal Cancer; FOLFIRI, leucovorin, fluorouracil, and irinotecan; FOLFOX, leucovorin, fluorouracil, and
oxaliplatin; FOLFOXIRI, leucovorin, fluorouracil, oxaliplatin, and irinotecan; HR, hazard ratio; mCRC, metastatic colorectal cancer; mFOLFOXIRI, modified FOLFOXIRI; NA, not applicable;
OPUS, Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer; PEAK, Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab Plus
mFOLOFOX6 inmCRCSubjectsWithWild-Type KRAS Tumors; PFS, progression-free survival; PRIME, Panitumumab Randomized Trial in CombinationWith Chemotherapy for Metastatic
Colorectal Cancer to Determine Efficacy; OR, odds ratio; ORR, objective response rate; OS, overall survival.
panitumumab; however, the results did not reach statistical
significance (96). Although ∼86% of the currently published
data for first-line studies of anti-EGFR agents vs. bevacizumab
in left-sided tumors come from cetuximab trials, studies
suggest similar results with either cetuximab or panitumumab
compared with bevacizumab in patients with RAS wt,
left-sided mCRC.
Although patients with right-sided tumors consistently had
worse prognoses than patients with left-sided tumors, they
may still derive tumor shrinkage benefits with anti-EGFR-
mAb-based treatment, according to a meta-analysis by Wang
et al. (including the CRYSTAL, TAILOR, PRIME, and 20050181
trials) that demonstrated that anti-EGFR-mAb-based treatment
significantly improves response rates and PFS in patients
with RAS wt mCRC, independent of primary tumor location
(97). Additionally, a meta-analysis by Arnold et al. (including
the CRYSTAL, FIRE-3, CALGB 80405, PRIME, PEAK, and
20050181 studies) confirmed the prognostic value of primary
tumor location and demonstrated that patients with left-sided
tumors significantly benefited from an anti-EGFR antibody plus
chemotherapy vs. chemotherapy with or without bevacizumab.
For patients with right-sided disease, there was no significant
benefit in OS or PFS; however, an analysis of ORR showed that an
anti-EGFR plus chemotherapy doublet can be a treatment option
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when cytoreduction is the goal (68). The findings of both meta-
analyses support the preferential utilization of an anti-EGFR
mAb plus chemotherapy in patients with RAS wt, left-sided
mCRC, with most of the data being extracted from cetuximab-
based trials. Although patients with right-sided tumors tended
to derive limited benefit from available therapy, a pooled
analysis of prospective trials showed that some proportion of
patients with right-sided tumors could respond to cetuximab,
suggesting that some patients with right-sided disease may
benefit from an anti-EGFR agent plus chemotherapy as an initial
treatment (98).
Although cetuximab and panitumumab have not been
compared directly in first- or second-line mCRC, a limited
number of phase 2 studies exist for each that had comparable
trial designs. A phase 2 trial by Carrato et al. evaluated the
efficacy of second-line panitumumab plus irinotecan in patients
with KRAS wt mCRC who had received either 5-FU, oxaliplatin,
or irinotecan in the first line. Panitumumab plus irinotecan
yielded a PFS and OS of 4.5 and 15.1 months, respectively,
and an ORR of 23%. The outcomes observed by Hong et al.
with second-line cetuximab plus irinotecan, also in patients
with KRAS wt disease, were a median PFS and OS of 8.3
and 18.3 months, respectively, and an ORR of 45% (99, 100).
The only randomized, phase 3 trial to compare cetuximab and
panitumumab directly was ASPECCT, which confirmed the
non-inferiority of panitumumab compared with cetuximab as
a monotherapy in the third- and later-line setting in patients
with KRAS wt mCRC. Results of the RAS wt subset of the
ASPECCT study are still pending (101). In the final analysis,
median PFS and OS were 4.1 vs. 4.4 months and 10.4 vs.
10.0 months with panitumumab vs. cetuximab, respectively.
The ORR was 22.0% with panitumumab and 19.8% with
cetuximab. ASPECCT was a non-inferiority trial (rather than
a superiority trial), but a trial powered to investigate efficacy
differences between cetuximab and panitumumab in colorectal
cancer had not been conducted at the time of this article.
Therefore, the results from ASPECCT might not be extrapolated
to earlier lines of therapy and to treatment in combination
with chemotherapy. One other noteworthy study, the phase
2, randomized WJOG6510G trial, compared cetuximab plus
irinotecan and panitumumab plus irinotecan in patients with
KRAS wt mCRC in whom 5-FU–, oxaliplatin-, and irinotecan-
based therapy had previously failed. The results suggested non-
inferiority of panitumumab plus irinotecan compared with
cetuximab plus irinotecan in this setting (102). Additional
third- and further-line studies of cetuximab or panitumumab
monotherapy or in combination with irinotecan are difficult
to compare directly because many of the early trials with
cetuximab were conducted prior to the discovery of the KRAS
mutation biomarker, and therefore enrollment was determined
by EGFR expression status only (103–110). However, the phase
3 CO.17 trial demonstrated how mutation status of the KRAS
gene was associated with OS in mCRC patients treated with
cetuximab after prior chemotherapy (111). More recently, a
retrospective analysis of the EPIC study demonstrated that post-
study cetuximab was associated with improved OS in the RAS wt
population (112).
One final difference in clinical efficacy that has been
observed between cetuximab and panitumumab concerns
the effect of prior bevacizumab treatment on response to
subsequent anti-EGFR therapy. Recent evidence has suggested
that prior bevacizumab therapy, if administered within a
certain time interval of initiation of anti-EGFR therapy,
can compromise responsiveness to cetuximab but not to
panitumumab (101, 113–117). These findings not only underline
the fact that the two mAbs are non-interchangeable, but they
also have implications in treatment sequencing—namely, that
in order to maximize the potential number of therapeutic
lines of treatment, cetuximab should be administered prior
to bevacizumab.
TABLE 4A | Comparison of cetuximab- and panitumumab-associated grade 3/4 adverse events: evidence from (A) first-line and (B) third-line phase 3 trials.
Adverse event (%) Treatment regimen
RAS wt RAS wt KRAS wt*
CRYSTAL (66) (cetuximab +
FOLFIRI)
TAILOR (69) (cetuximab +
FOLFOX4)
PRIME (65, 118)
(panitumumab + FOLFOX4)
Any AE 81 94 57 with grade 3, 28 with grade 4*
Diarrhea 15 6 18
Hypomagnesemia NR 8 7
Infusion-related
reactions
2 10 <1
Neurotoxicity NR NR 16
Skin reactions 21 26 37
Acne-like rash 17 24 NR
*Data shown for PRIME, any AE, is from a RAS wt analysis. All other AE data shown for PRIME are from the KRAS wt population.
AE, adverse event; CRC, colorectal cancer; CRYSTAL, Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer; FOLFIRI, leucovorin, fluorouracil, and
irinotecan; FOLFOX, leucovorin, fluorouracil, and oxaliplatin; PRIME, Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine
Efficacy; wt, wild type.
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TABLE 4B | Evidence from the phase 3, head-to-head ASPECCT trial in 3L KRAS
wt mCRC patients (101).
Adverse event (%) Treatment
Cetuximab Panitumumab
Any AE 494 (98) 485 (98)
Grade 3/Grade 4 AEs
Diarrhea 9 (2)/0 7 (1)/3 (1)
Hypomagnesemia 10 (2)/3 (<1) 26 (5)/9 (2)
Infusion-related reactions 5 (1)/4 (<1) 1 (<0·5)/0
Neurotoxicity Not reported Not reported
Skin reactions 48 (10)/0 60 (12)/2 (<0·5)
Acne-like rash 14 (3)/0 17 (3)/0
SAFETY FINDINGS WITH CETUXIMAB AND
PANITUMUMAB IN COLORECTAL CANCER
The rates of grade 3/4 adverse events (AEs) considered related to
anti-EGFR therapy in patients treated with first-line anti-EGFR
plus chemotherapy are presented in Table 4A. Additionally,
the rates of grade 3/4 AEs from the third-line head-to-head
ASPECCT trial are presented in Table 4B.
Although a direct comparison is confounded by the lack
of AE rates for RAS wt patients in PRIME (the PRIME trial
did not present rates of individual AEs for the RAS subgroup),
the addition of cetuximab to chemotherapy was associated
with an increased incidence of grade 3/4 infusion-related
reactions, whereas the addition of panitumumab exacerbated
the incidence of grade 3/4 diarrhea (65, 66, 69, 118). A meta
analysis by Petrelli et al. concluded that while cetuximab and
panitumumab have a similar burden of overall toxicity in
terms of severe AEs, the individual safety profiles are distinct.
Panitumumab was associated with a higher rates of grade
3/4 skin toxicities, hypomagnesemia, fatal AEs, and treatment
discontinuations, while cetuximab was associated with a higher
rates of skin rash, infusion reactions, and gastrointestinal toxicity
(119). As noted in Petrelli et al., the third-line, anti-EGFR
monotherapy trial ASPECCT also identified increased rates of
grade 3/4 hypomagnesemia and decreased rates of infusion-
related reactions with panitumumab compared with cetuximab
(101). Finally, whereas the CRYSTAL and TAILOR trials reported
no treatment-related grade 3/4 neurotoxicity occurring at a rate
of ≥5% frequency in either arm, a rate of 16% was reported
in the patient population of the PRIME trial (118). Petrelli
et al. similarly identified a higher rate of grade 3/4 neurotoxicity
in panitumumab trials than in cetuximab trials (119). The
reasons for the increased incidence of (likely oxaliplatin-related)
neurotoxicity (120) in panitumumab trials remain unknown.
Regarding chemotherapy backbones for the two mAbs, the
selection of FOLFIRI vs. FOLFOX for first-line treatment can
depend on which toxicity profile is likely to be more tolerable
for the patient in question, because the two regimens are
considered to have similar activities in mCRC (2). Therefore,
differences in the toxicity profiles between the two chemotherapy
backbones in combination with panitumumab vs. cetuximab
are of substantial clinical relevance during treatment selection.
However, it is worth noting that a meta-analysis by Teng et al.
found a slight improvement in time to progression, and thus
in OS, with FOLFIRI followed by FOLFOX compared with the
reverse sequence (121). This finding reinforces the importance
of treatment sequencing and how the differential findings with
cetuximab and panitumumab can be applied, namely, that
cetuximab has been shown to pair well with either FOLFOX or
FOLFIRI vs. FOLFOX or FOLFIRI alone, whereas all available
phase 3 data for panitumumab efficacy in first-line mCRC are
in combination with FOLFOX. Notably, there are several small
studies, although without comparator arms, that have provided
evidence for the activity of panitumumab in combination with
FOLFIRI in mCRC (87, 90).
EFFICACY WITH CETUXIMAB AND
PANITUMUMAB IN HEAD AND NECK
CANCER
As previously mentioned, cetuximab has been approved for
use in combination with radiotherapy in locally advanced
SCCHN (LA SCCHN) and in combination with platinum and
5-FU, followed by cetuximab maintenance, for recurrent and/or
metastatic SCCHN (R/M SCCHN) (122, 123). Panitumumab
has been investigated in combination with radiotherapy in LA
SCCHN but has failed to improve upon the current standard-
of-care chemoradiotherapy treatment (124, 125), and it did not
demonstrate a significant improvement in OS when added to
platinum plus 5-FU chemotherapy in the R/M setting (126).
A caveat is that panitumumab maintenance was optional in
the SPECTRUM trial, following panitumumab plus platinum
and 5-FU in patients with first-line R/M SCCHN, whereas
cetuximab maintenance therapy in the EXTREME trial was
given to all patients who achieved stable disease or a response
during combination treatment (126, 127). Therefore, we are
unable to directly compare the two agents in the SCCHN
setting (Tables 5A,B). What can be said with certainty is that
cetuximab is highly active in SCCHN, and proposed explanations
include the increased potential contribution of cetuximab’s
immune actions in this tumor type, given the predominance of
EGFR-overexpressing cells and immunologic sensitivity in head
and neck tumors (25). Specifically, cetuximab’s stimulation of
ADCC and other immunostimulatory activities (DC maturation,
T-cell recruitment to the tumor, increased antigen presentation,
and cytotoxic T-cell priming) are dependent on cetuximab’s
simultaneous binding of the EGFR and the CD16 receptor
on NK cells (25). Indeed, evidence has suggested the link
between high baseline ADCC and EGFR overexpression and
better outcomes with cetuximab plus radiotherapy but not with
chemoradiotherapy (55). Thus, while it is difficult to prove
the clinical impact of cetuximab-driven immunostimulation on
tumor cell death, tumor shrinkage, and disease control, a wealth
of evidence suggests that it is, in fact, a contributing factor to
cetuximab’s antitumor activity in SCCHN (25), and it may be the
key differentiating aspect between cetuximab and panitumumab
in head and neck cancer.
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TABLE 5A | Clinical impact of cetuximab and panitumumab in LA SCCHN.
Study Treatment regimen Patients, n LRC rate
(2 years)
OS rate (2
years)
Safety findings
IMCL-9815
(Bonner trial) (128)
Radiotherapy vs.
radiotherapy +
cetuximab
213 vs. 211 41 vs. 50% 55 vs. 62% Grade 3–5 mucositis (52 vs. 56%), acneiform rash
(1 vs. 17%), radiation dermatitis (18 vs. 23%),
weight loss (7 vs. 11%), xerostomia (3 vs. 5%),
dysphagia (30 vs. 26%), asthenia (5 vs. 4%),
constipation (5 vs. 5%), pain (7 vs. 6%), and
dehydration (8 vs. 6%)
CONCERT-2 (124) Chemoradiotherapy vs.
radiotherapy +
panitumumab
61 vs. 90 61 vs. 51% 71 vs. 63% Grade 3/4 mucositis (40 vs. 42%), dysphagia (32
vs. 40%), radiation skin injury (11 vs. 24%). Serious
AEs were more frequent in the chemoradiotherapy
arm (40 vs. 34%)
Siu et al. (125) Chemoradiotherapy vs.
radiotherapy +
panitumumab
156 vs. 159 73 vs. 76%
(2-year PFS
rate)
85 vs. 88% Grade ≥ 3 non-hematologic AEs occurred at rates
of 88 vs. 91%, respectively
TABLE 5B | Clinical impact of cetuximab and panitumumab in R/M SCCHN.
Study Treatment regimen Patients, n Median PFS, months Median OS, months Safety findings
EXTREME
(127)
Cisplatin/carboplatin +
5-FU + cetuximab→
maintenance cetuximab vs.
Cisplatin/carboplatin +
5-FU
222 vs. 220 5.6 vs. 3.3 (HR, 0.54
[95% CI, 0.43–0.67];
P < 0.001)
10.1 vs. 7.4 (HR, 0.80
[95% CI, 0.64–0.99];
P = 0.04)
Grade 3/4 neutropenia (22 vs. 23%),
anemia (13 vs. 19%),
thrombocytopenia (11 vs. 11%), skin
reactions (9 vs. < 1%)
SPECTRUM
(126)
Cisplatin/carboplatin +
5-FU + panitumumab→
maintenance panitumumab
q3w (optional) vs.
Cisplatin/carboplatin +
5-FU
327 vs. 330 5.8 vs. 4.6 (HR, 0.78
[95% CI, 0.659–0.922];
P = 0.0036)
11.1 vs. 9.0 (HR, 0.873
[95% CI, 0.729–1.046];
P = 0.1403)
Grade 3/4 skin or eye toxicity (19%),
diarrhea (5%), hypomagnesemia
(12%), hypokalemia (10%), and
dehydration (5%) were more frequent
in the panitumumab arm vs. control.
4% treatment-related deaths
occurred in the panitumumab arm
5-FU, fluorouracil; AE, adverse event; CONCERT-2, Concomitant Chemotherapy and/or EGFR Inhibition With Radiation Therapy; EXTREME, Erbitux in First-Line Treatment of Recurrent
or Metastatic Head and Neck Cancer; HR, hazard ratio; LA, locally advanced; LRC, locoregional control; OS, overall survival; PFS, progression-free survival; q3w, every 3 weeks; R/M,
recurrent and/or metastatic; SCCHN, squamous cell carcinoma of the head and neck; SPECTRUM, Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head
and Neck Cancer.
POTENTIAL OF ANTI-EGFR mAbs IN
COMBINATION WITH IMMUNOTHERAPY
REGIMENS
Cetuximab and panitumumab behave differently, despite their
therapeutic targeting of the same receptor; thus, available clinical
data for one should not be applied to the other. Looking to the
future in mCRC treatment, emerging immunotherapies have yet
to demonstrate paradigm-shifting clinical activity in mismatch
repair–proficient mCRC (129), suggesting that the way forward
will continue to be combinatorial, including chemotherapy
elements. In this respect, irinotecan’s and oxaliplatin’s synergistic
effects with cetuximab (130–132) and possible differences from
a treatment-sequencing standpoint suggest that cetuximab plus
either FOLFIRI or FOLFOX is a suitable combination partner
for checkpoint inhibitors and other immunotherapies. For
example, cetuximab induces NK cell–mediated ADCC, resulting
in increased immunogenic cell death, and cetuximab-treated cells
have been shown to be more susceptible to phagocytosis by DCs.
In the same study by Pozzi et al., even measurable immunogenic
cell death occurred when CRC cell lines and mouse CRC models
were co-treated with cetuximab plus FOLFIRI (31). Similarly,
oxaliplatin has been shown to have some immunostimulatory
properties, including immunogenic cell death (133–136) and the
ability to prime tumors for checkpoint blockade in preclinical
models (11, 136, 137). Cetuximab’s known immune actions,
including increasing immune infiltration and immune visibility
of the tumor, suggest that it will be the more potent combination
partner for either irinotecan- or oxaliplatin-based therapy, to
which checkpoint inhibitors may theoretically be added to
increase the immune antitumor response.
CONCLUSIONS AND FUTURE
DIRECTIONS FOR CETUXIMAB AND
PANITUMUMAB
Cetuximab and panitumumab are both currently used to treat
RAS wt mCRC. Clinical data for panitumumab in combination
with chemotherapy is mostly limited to FOLFOX in the first-
line setting, whereas cetuximab has demonstrated efficacy and
safety in phase 3 first-line trials with both FOLFOX and
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FOLFIRI. Additionally, their combinability with FOLFIRI and
known activity following prior bevacizumab treatment may have
implications for optimal treatment sequencing in the continuum
of care for mCRC.
Aside from the fact that panitumumab is a human
mAb and cetuximab is a mouse/human chimeric mAb,
the two anti-EGFR agents are composed of different IgG
isotypes. Because cetuximab is an IgG1 mAb, it has additional
immunogenic activity not demonstrated by panitumumab
(IgG2). Cetuximab, unlike panitumumab, can prime the tumor
microenvironment for an immune attack by enabling multiple
processes, including ADCC and activation of innate and
adaptive immune effector cells. Interestingly, both cetuximab
and panitumumab improve outcomes in CRC. Despite extensive
immune system activation induced by cetuximab, residual
tumor-associated cells can prevent the final attack of cytotoxic
T cells on the tumor by upregulation of PD-1, PD-L1, and
CTLA-4 on their surface or by releasing cytokines such as
TGF-β or chemokines such as CXCL12, which inactivate
effector cells (25). Whether cetuximab will be clinically superior
to panitumumab in the immunotherapy era remains to
be determined by future clinical trials employing immune
checkpoint inhibitors, which may complement the “immune
priming” activity of cetuximab (and chemotherapy). We
eagerly anticipate upcoming results from future and ongoing
clinical trials.
AUTHOR CONTRIBUTIONS
All authors contributed equally to the conception of the
intellectual content, interpretation of the data, and writing
of the manuscript. All authors also reviewed any revisions
that were made and provided their final approval of
the manuscript.
ACKNOWLEDGMENTS
Medical writing assistance was provided by Ina Nikolaeva, Ph.D.,
of ClinicalThinking, Inc., Hamilton, NJ, USA, and funded by
Merck Healthcare KGaA, Darmstadt, Germany.
REFERENCES
1. Shim H. One target, different effects: a comparison of distinct therapeutic
antibodies against the same targets. Exp Mol Med. (2011) 43:539–49.
doi: 10.3858/emm.2011.43.10.063
2. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH,
Aderka D, et al. ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol. (2016) 27:1386–422.
doi: 10.1093/annonc/mdw235
3. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. V2.2018.
Fort Washington, PA: National Comprehensive Cancer Network (2018).
4. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR
monoclonocal antibodies: focus on panitumumab. Biologics. (2008) 2:223–8.
doi: 10.2147/BTT.S1980
5. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli
A. Resistance to anti-EGFR therapy in colorectal cancer: from
heterogeneity to convergent evolution. Cancer Discov. (2014) 4:1269–80.
doi: 10.1158/2159-8290.CD-14-0462
6. Erbitux (cetuximab). Summary of Product Characteristics. Available
online at: https://www.ema.europa.eu/en/documents/product-information/
erbitux-epar-product-information_en.pdf (accessed 22 July, 2019).
7. Vectibix (panitumumab). Summary of Product Characteristics. Available
online at: https://www.ema.europa.eu/en/documents/product-information/
vectibix-epar-product-information_en.pdf (accessed 22 July, 2019).
8. Amgen Press Release. (2016). Available online at: https://www.amgen.
com/media/news-releases/2016/10/new-retrospective-analyses-confirm-
vectibix-panitumumab-treatment-provided-survival-benefit-over-
chemotherapy-with-or-without-bevacizumab-in-metastatic-colorectal-
cancer-patients-with-tumors-of-leftsided-origin/ (accessed March 2018).
9. Merck KGaA Press Release. (2017). Available online at: https://www.ots.
at/presseaussendung/OTE_20170302_OTE0001/nice-expands-positive-
recommendation-for-erbitux-as-first-line-treatment-for-ras-wild-type-
mcrc (accessed March 2018).
10. Park NJ, Wang X, Diaz A, Goos-Root DM, Bock C, Vaught JD,
et al. Measurement of cetuximab and panitumumab-unbound serum
EGFR extracellular domain using an assay based on slow off-rate
modified aptamer (SOMAmer) reagents. PLoS ONE. (2013) 8:e71703.
doi: 10.1371/journal.pone.0071703
11. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, et al.
Impact of intrinsic affinity on functional binding and biological
activity of EGFR antibodies. Mol Cancer Ther. (2012) 11:1467–76.
doi: 10.1158/1535-7163.MCT-11-1038
12. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, et al. Epidermal growth
factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance
escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Cancer Res. (2007) 67:8240–7. doi: 10.1158/0008-5472.CAN-07-0589
13. Sickmier EA, Kurzeja RJ, Michelsen K, Vazir M, Yang E, Tasker AS.
The panitumumab EGFR complex reveals a binding mechanism that
overcomes cetuximab induced resistance. PLoS ONE. (2016) 11:e0163366.
doi: 10.1371/journal.pone.0163366
14. Qin S, Xu JM, Wang L, Cheng Y, Liu TS, Chen J, et al. Impact of tumor
epidermal growth factor receptor (EGFR) status on the outcomes of first-line
FOLFOX-4± cetuximab in patients (pts) with RAS-wild-type (wt)metastatic
colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial. Ann
Oncol. (2016) 27(suppl. 6):527. doi: 10.1093/annonc/mdw370.75
15. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, et al.
Functional dissection of the epidermal growth factor receptor epitopes
targeted by panitumumab and cetuximab. Neoplasia. (2012) 14:1023–31.
doi: 10.1593/neo.121242
16. Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt
NC, et al. Immune biomarkers of anti-EGFR monoclonal antibody therapy.
Ann Oncol. (2015) 26:40–7. doi: 10.1093/annonc/mdu156
17. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli
E, et al. Cetuximab administered once every second week to patients with
metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic
phase I dose-escalation study. Ann Oncol. (2010) 21:1537–45.
doi: 10.1093/annonc/mdp549
18. Krens LL, Baas JM, Guchelaar HJ, Gelderblom H. Pharmacokinetics and
safety of panitumumab in a patient with chronic kidney disease. Cancer
Chemother Pharmacol. (2018) 81:179–82. doi: 10.1007/s00280-017-3479-2
19. Lo L, Patel D, Townsend AR, Price TJ. Pharmacokinetic and
pharmacodynamic evaluation of panitumumab in the treatment of
colorectal cancer. Expert Opin Drug Metab Toxicol. (2015) 11:1907–24.
doi: 10.1517/17425255.2015.1112787
20. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, et al.
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis
in human transitional cell carcinoma growing orthotopically in nude mice.
Clin Cancer Res. (1999) 5:257–65.
21. Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F,
et al. Angiogenesis modifications related with cetuximab plus irinotecan
Frontiers in Oncology | www.frontiersin.org 12 September 2019 | Volume 9 | Article 849
García-Foncillas et al. Two Distinct Anti-EGFRs: Cetuximab and Panitumumab
as anticancer treatment in advanced colorectal cancer patients. Ann Oncol.
(2006) 17:835–41. doi: 10.1093/annonc/mdl031
22. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L,
Seethala RR, et al. STAT1-induced HLA class I upregulation enhances
immunogenicity and clinical response to anti-EGFR mAb cetuximab
therapy in HNC patients. Cancer Immunol Res. (2015) 3:936–45.
doi: 10.1158/2326-6066.CIR-15-0053
23. Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini
G, et al. Cetuximab +/- chemotherapy enhances dendritic cell-mediated
phagocytosis of colon cancer cells and ignites a highly efficient colon cancer
antigen-specific cytotoxic T-cell response in vitro. Int J Cancer. (2012)
130:1577–89. doi: 10.1002/ijc.26181
24. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson
HC, et al. Cetuximab-activated natural killer and dendritic cells
collaborate to trigger tumor antigen-specific T-cell immunity in
head and neck cancer patients. Clin Cancer Res. (2013) 19:1858–72.
doi: 10.1158/1078-0432.CCR-12-2426
25. Ferris RL, Lenz HJ, Trotta AM, Garcia-Foncillas J, Schulten J, Audhuy F, et al.
Rationale for combination of therapeutic antibodies targeting tumor cells
and immune checkpoint receptors: harnessing innate and adaptive immunity
through IgG1 isotype immune effector stimulation. Cancer Treat Rev. (2018)
63:48–60. doi: 10.1016/j.ctrv.2017.11.008
26. Xynos ID, Karadima ML, Voutsas IF, Amptoulach S, Skopelitis E, Kosmas
C, et al. Chemotherapy +/- cetuximab modulates peripheral immune
responses in metastatic colorectal cancer. Oncology. (2013) 84:273–83.
doi: 10.1159/000343282
27. Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM,
Li J, et al. Anti-EGFR targeted monoclonal antibody isotype influences anti-
tumor cellular immunity in head and neck cancer patients. Clin Cancer Res.
(2016) 22:5229–37. doi: 10.1158/1078-0432.CCR-15-2971
28. Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis
C, et al. Prospective evaluation of cetuximab-mediated antibody-
dependent cell cytotoxicity in metastatic colorectal cancer patients
predicts treatment efficacy. Cancer Immunol Res. (2016) 4:366–74.
doi: 10.1158/2326-6066.CIR-15-0184
29. Holubec L, Polivka J Jr, Safanda M, Karas M, Liska V. The role of cetuximab
in the induction of anticancer immune response in colorectal cancer
treatment. Anticancer Res. (2016) 36:4421–6. doi: 10.21873/anticanres.10985
30. Chen S, Li X, Chen R, Yin M, Zheng Q. Cetuximab intensifies the ADCC
activity of adoptive NK cells in a nude mouse colorectal cancer xenograft
model. Oncol Lett. (2016) 12:1868–76. doi: 10.3892/ol.2016.4835
31. Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, et al. The
EGFR-specific antibody cetuximab combined with chemotherapy triggers
immunogenic cell death. Nat Med. (2016) 22:624–31. doi: 10.1038/nm.4078
32. Melero I, Rouzaut A,Motz GT, Coukos G. T-cell and NK-cell infiltration into
solid tumors: a key limiting factor for efficacious cancer immunotherapy.
Cancer Discov. (2014) 4:522–6. doi: 10.1158/2159-8290.CD-13-0985
33. Motz GT, Coukos G. The parallel lives of angiogenesis and
immunosuppression: cancer and other tales. Nat Rev Immunol. (2011)
11:702–11. doi: 10.1038/nri3064
34. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al.
Tumor endothelium FasL establishes a selective immune barrier promoting
tolerance in tumors. Nat Med. (2014) 20:607–15. doi: 10.1038/nm.3541
35. Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika
S, et al. Cetuximab strongly enhances immune cell infiltration into
liver metastatic sites in colorectal cancer. Cancer Sci. (2017) 108:455–60.
doi: 10.1111/cas.13162
36. Maeda K, Hazama S, Tokuno K, Kan S, Maeda Y, Watanabe Y, et al. Impact
of chemotherapy for colorectal cancer on regulatory T-cells and tumor
immunity. Anticancer Res. (2011) 31:4569–74.
37. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al.
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor
cells resulting in enhanced T cell-dependent antitumor immunity. Cancer
Res. (2010) 70:3052–61. doi: 10.1158/0008-5472.CAN-09-3690
38. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural
killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal
antibody triggers tumor antigen-specific T cell immunity. Immunol Res.
(2011) 50:248–54. doi: 10.1007/s12026-011-8231-0
39. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and
metastatic potential in human squamous cell carcinomas after epidermal
growth factor receptor blockade.Mol Cancer Ther. (2002) 1:507–14.
40. Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder
C, Ferrone S, et al. CD137 Stimulation enhances cetuximab-induced
natural killer: dendritic cell priming of antitumor T-cell immunity in
patients with head and neck cancer. Clin Cancer Res. (2017) 23:707–16.
doi: 10.1158/1078-0432.CCR-16-0879
41. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al.
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. (2014)
124:2668–82. doi: 10.1172/JCI73014
42. Lopez-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang
X, Gooding W, et al. Maturation pathways of dendritic cells determine
TAP1 and TAP2 levels and cross-presenting function. J Immunother. (2009)
32:465–73. doi: 10.1097/CJI.0b013e3181a1c24e
43. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese
A, et al. Immune-modulating effects of the newest cetuximab-based
chemoimmunotherapy regimen in advanced colorectal cancer patients. J
Immunother. (2012) 35:440–7. doi: 10.1097/CJI.0b013e31825943aa
44. Schoppy DW, Sunwoo JB. Immunotherapy for head and neck squamous
cell carcinoma. Hematol Oncol Clin North Am. (2015) 29:1033–43.
doi: 10.1016/j.hoc.2015.07.009
45. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer
cells-enhancement by therapeutic antibodies. PLoS ONE. (2007) 2:e326.
doi: 10.1371/journal.pone.0000326
46. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, et al.
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural
killer cells toward osteosarcoma. Clin Cancer Res. (2012) 18:432–41.
doi: 10.1158/1078-0432.CCR-11-2277
47. Krawczyk PA, Kowalski DM. Genetic and immune factors underlying
the efficacy of cetuximab and panitumumab in the treatment of patients
with metastatic colorectal cancer. Contemp Oncol (Pozn). (2014) 18:7–16.
doi: 10.5114/wo.2013.38566
48. Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H. IgG1 anti-epidermal
growth factor receptor antibodies induce CD8-dependent antitumor activity.
Int J Cancer. (2015) 136:821–30. doi: 10.1002/ijc.29037
49. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improved survival with ipilimumab in patients with metastatic melanoma.N
Engl J Med. (2010) 363:711–23. doi: 10.1056/NEJMoa1003466
50. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S,
et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level
in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and
neck squamous cell carcinoma cells. Cancer Immunol Immunother. (2009)
58:1853–64. doi: 10.1007/s00262-009-0697-4
51. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS,
Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody
therapy for relapsed indolent lymphoma: half of patients respond
to a four-dose treatment program. J Clin Oncol. (1998) 16:2825–33.
doi: 10.1200/JCO.1998.16.8.2825
52. Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, et al.
The relevance of ADCC for EGFR targeting: a review of the literature and
a clinically-applicable method of assessment in patients. Crit Rev Oncol
Hematol. (2015) 95:179–90. doi: 10.1016/j.critrevonc.2015.02.014
53. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis
S, et al. Increased natural killer cell expression of CD16, augmented
binding and ADCC activity to rituximab among individuals expressing the
Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. (2007) 110:2561–
4. doi: 10.1182/blood-2007-01-070656
54. Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM II, Greiner JW, et al.
An NK cell line (haNK) expressing high levels of granzyme and engineered
to express the high affinity CD16 allele. Oncotarget. (2016) 7:86359–73.
doi: 10.18632/oncotarget.13411
55. Lattanzio L, Denaro N, Vivenza D, Varamo C, Strola G, Fortunato M, et al.
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and
high epidermal growth factor receptor (EGFR) expression predict favourable
outcome in patients with locally advanced head and neck cancer treated
with cetuximab and radiotherapy. Cancer Immunol Immunother. (2017)
66:573–9. doi: 10.1007/s00262-017-1960-8
Frontiers in Oncology | www.frontiersin.org 13 September 2019 | Volume 9 | Article 849
García-Foncillas et al. Two Distinct Anti-EGFRs: Cetuximab and Panitumumab
56. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T,
et al. Complement-dependent tumor cell lysis triggered by combinations of
epidermal growth factor receptor antibodies. Cancer Res. (2008) 68:4998–
5003. doi: 10.1158/0008-5472.CAN-07-6226
57. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer
MA, et al. Complement is activated by IgG hexamers assembled at the cell
surface. Science. (2014) 343:1260–3. doi: 10.1126/science.1248943
58. De RoockW, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G,
et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy
of cetuximab plus chemotherapy in chemotherapy-refractory metastatic
colorectal cancer: a retrospective consortium analysis. Lancet Oncol. (2010)
11:753–62. doi: 10.1016/S1470-2045(10)70130-3
59. Foltran L, De Maglio G, Pella N, Ermacora P, Aprile G, Masiero E, et al.
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced
colorectal cancer. Future Oncol. (2015) 11:629–40. doi: 10.2217/fon.14.279
60. Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari
L, et al. Emergence of multiple EGFR extracellular mutations during
cetuximab treatment in colorectal cancer. Clin Cancer Res. (2015) 21:2157–
66. doi: 10.1158/1078-0432.CCR-14-2821
61. Bouchahda M, Karaboue A, Saffroy R, Innominato P, Gorden L, Guettier
C, et al. Acquired KRAS mutations during progression of colorectal
cancer metastases: possible implications for therapy and prognosis. Cancer
Chemother Pharmacol. (2010) 66:605–9. doi: 10.1007/s00280-010-1298-9
62. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A,
Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade
in the blood of colorectal cancer patients. Nat Med. (2015) 21:827.
doi: 10.1038/nm0715-827b
63. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR,
et al. PEAK: a randomized, multicenter phase II study of panitumumab
plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or
bevacizumab plus mFOLFOX6 in patients with previously untreated,
unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin
Oncol. (2014) 32:2240–7. doi: 10.1200/JCO.2013.53.2473
64. Peeters M, Oliner K, Parker A, Siena S, Van Cutsem E, Huang J,
et al. Massively parallel tumor multigene sequencing to evaluate
response to panitumumab in a randomized phase III study of
metastatic colorectal cancer. Clin Cancer Res. (2013) 19:1902–12.
doi: 10.1158/1078-0432.CCR-12-1913
65. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M,
et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal
cancer. N Engl J Med. (2013) 369:1023–34. doi: 10.1056/NEJMoa13
05275
66. Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezinek
I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment
and RAS mutations in colorectal cancer. J Clin Oncol. (2015) 33:692–700.
doi: 10.1200/JCO.2014.59.4812
67. Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal
LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus
bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis
of tumour dynamics in the final RAS wild-type subgroup of this
randomised open-label phase 3 trial. Lancet Oncol. (2016) 17:1426–34.
doi: 10.1016/S1470-2045(16)30269-8
68. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al.
Prognostic and predictive value of primary tumour side in patients with RAS
wild-type metastatic colorectal cancer treated with chemotherapy and EGFR
directed antibodies in six randomised trials. Ann Oncol. (2017) 28:1713–29.
doi: 10.1093/annonc/mdx175
69. Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al. Efficacy and tolerability of
first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-
4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal
cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol.
(2018) 36:3031–9. doi: 10.1200/JCO.2018.78.3183
70. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D,
et al. Emergence of KRAS mutations and acquired resistance to
anti-EGFR therapy in colorectal cancer. Nature. (2012) 486:532–6.
doi: 10.1038/nature11156
71. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al.
Cetuximab rechallenge in metastatic colorectal cancer patients: how to
come away from acquired resistance? Ann Oncol. (2012) 23:2313–8.
doi: 10.1093/annonc/mdr623
72. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, et al.
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer:
impact of intervening time interval and prior anti-EGFR response. BMC
Cancer. (2015) 15:713. doi: 10.1186/s12885-015-1701-3
73. Rossini D, Cremolini C, Conca E, Del Re M, Busico A, Pietrantonio F,
et al. Liquid biopsy to predict benefit from rechallenge with cetuximab
(cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer
patients (pts) with acquired resistance to first-line cet+iri: final results and
translational analyses of the CRICKET study by GONO. J Clin Oncol. (2018)
36(suppl):12007. doi: 10.1200/JCO.2018.36.15_suppl.12007
74. Sanchez-Martin FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Canadas
I, Vidal J, et al. The first-in-class anti-EGFR antibody mixture Sym004
overcomes cetuximab resistance mediated by EGFR extracellular domain
mutations in colorectal cancer. Clin Cancer Res. (2016) 22:3260–7.
doi: 10.1158/1078-0432.CCR-15-2400
75. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al.
Identification of a mutation in the extracellular domain of the Epidermal
Growth Factor Receptor conferring cetuximab resistance in colorectal
cancer. Nat Med. (2012) 18:221–3. doi: 10.1038/nm.2609
76. Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti
G, et al. Acquired RAS or EGFR mutations and duration of response
to EGFR blockade in colorectal cancer. Nat Commun. (2016) 7:13665.
doi: 10.1038/ncomms13665
77. Braig F, Marz M, Schieferdecker A, Schulte A, Voigt M, Stein A, et al.
Epidermal growth factor receptor mutation mediates cross-resistance to
panitumumab and cetuximab in gastrointestinal cancer. Oncotarget. (2015)
6:12035–47. doi: 10.18632/oncotarget.3574
78. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt
JA, et al. Effect of first-line chemotherapy combined with cetuximab or
bevacizumab on overall survival in patients with KRAS wild-type advanced
or metastatic colorectal cancer: a randomized clinical trial. JAMA. (2017)
317:2392–401. doi: 10.1001/jama.2017.7105
79. Khattak MA, Martin H, Davidson A, Phillips M. Role of first-line anti-
epidermal growth factor receptor therapy compared with anti-vascular
endothelial growth factor therapy in advanced colorectal cancer: a meta-
analysis of randomized clinical trials. Clin Colorectal Cancer. (2015) 14:81–
90. doi: 10.1016/j.clcc.2014.12.011
80. Venook AP, Neidzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil BH,
et al. Impact of primary (1◦) tumor location on overall survival (OS) and
progression-free survival (PFS) in patients (pts) with metastatic colorectal
cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). In: American
Society of Clinical Oncology 2016 Annual Meeting; June 03–07. Chicago, IL
(2016). doi: 10.1200/JCO.2016.34.15_suppl.3504
81. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson
RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination
chemotherapy for treatment of advanced colorectal cancer: results of
the randomised phase 3 MRC COIN trial. Lancet. (2011) 377:2103–14.
doi: 10.1016/j.yonc.2011.08.011
82. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud
F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab
in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. (2009)
27:663–71. doi: 10.1200/JCO.2008.20.8397
83. Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, HeinemannV, Klinkhardt U,
et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal
cancer. Eur J Cancer. (2015) 51:1243–52. doi: 10.1016/j.ejca.2015.04.007
84. Xu JM, Ren L,Wei Y, Zheng P, Ye LC, Feng QY, et al. Effects of beyond KRAS
mutations on the efficacy of cetuximab plus chemotherapy for patients with
unresectable colorectal liver-limited metastases (BELIEF): a prospective-
retrospective biomarker analysis of a Chinese trial. Eur J Cancer. (2016)
51:S369. doi: 10.1016/S0959-8049(16)31039-5
85. Antoniotti C, Cremolini C, Loupakis F, Bergamo F, Grande R, Tonini
G. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed
by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type
(wt) metastatic colorectal cancer (mCRC): results of the phase II
randomizedMACBETH trial by GONO. J Clin Oncol. (2016) 34(suppl):3543.
doi: 10.1200/JCO.2016.34.15_suppl.3543
Frontiers in Oncology | www.frontiersin.org 14 September 2019 | Volume 9 | Article 849
García-Foncillas et al. Two Distinct Anti-EGFRs: Cetuximab and Panitumumab
86. Cremolini C, Antoniotti C, Lonardi S, Aprile G, Bergamo F, Masi G, et al.
Activity and safety of cetuximab plus modified FOLFOXIRI followed by
maintenance with cetuximab or bevacizumab for RAS and BRAF wild-
type metastatic colorectal cancer: a randomized phase 2 clinical trial. JAMA
Oncol. (2018) 4:529–36. doi: 10.1001/jamaoncol.2017.5314
87. Carrato A, Abad A, Massuti B, Gravalos C, Escudero P, Longo-
Munoz F, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI
in colorectal cancer with multiple or unresectable liver metastases: a
randomised, phase II trial (PLANET-TTD). Eur J Cancer. (2017) 81:191–202.
doi: 10.1016/j.ejca.2017.04.024
88. Geissler M, Martens UM, Knorrenschield R, Greeve J, Florschuetz A,
Tannapfel A, et al. mFOLFOXIRI + panitumumab versus FOLFOXIRI
as first-line treatment in patients with RAS wild-type metastatic
colorectal cancer m(CRC): a randomized phase II VOLFI trial of
the AIO (AIO-KRK0109). Ann Oncol. (2017) 28(suppl. 5):475O.
doi: 10.1093/annonc/mdx393.002
89. Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis
K, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin
(LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI)
plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal
cancer: a pilot phase II trial. Br J Cancer. (2012) 107:1932–7. doi: 10.1038/bjc.
2012.509
90. Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, et al. First-
line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in
patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. (2012)
138:65–72. doi: 10.1007/s00432-011-1061-6
91. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y,
et al. Final results from a randomized phase 3 study of FOLFIRI {+/−}
panitumumab for second-line treatment of metastatic colorectal cancer.Ann
Oncol. (2014) 25:107–16. doi: 10.1093/annonc/mdt523
92. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, et al.
FOLFOXIRI in combination with panitumumab as first-line treatment in
quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal
cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest
(GONO). Ann Oncol. (2013) 24:2062–7. doi: 10.1093/annonc/mdt165
93. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H,
et al. Comparison of 17,641 patients with right- and left-sided colon
cancer: differences in epidemiology, perioperative course, histology, and
survival. Dis Colon Rectum. (2010) 53:57–64. doi: 10.1007/DCR.0b013e3181
c703a4
94. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier
F, et al. Prognostic and predictive relevance of primary tumor location
in patients with RAS wild-type metastatic colorectal cancer: retrospective
analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. (2017) 3:194–201.
doi: 10.1001/jamaoncol.2016.3797
95. Sagawa T, Hamaguchi K, Sakurada A, Tamura F, Hayashi T, Fujikawa
K, et al. Primary tumor location as a prognostic and predictive factor
in metastatic colorectal cancer (mCRC) treated with chemotherapy plus
cetuximab: a retrospective analysis. J Clin Oncol. (2017) 35(suppl):711.
doi: 10.1200/JCO.2017.35.4_suppl.711
96. Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena
S, et al. Primary tumor sidedness has an impact on prognosis and
treatment outcome in metastatic colorectal cancer: results from two
randomized first-line panitumumab studies. Ann Oncol. (2017) 28:1862–8.
doi: 10.1093/annonc/mdx119
97. Wang Z-X, He M-M, Wang Y-N, Wang F, Xu R-H. Predictive value of
primary tumor location (TL) in patients (pts) with pan-RAS wild-type
(wt) metastatic colorectal cancer (mCRC) receiving chemotherapy (CTX)±
cetuximab or panitumumab (C/P): an updated meta-analysis. J Clin Oncol.
(2018) 36(suppl):830. doi: 10.1200/JCO.2018.36.4_suppl.830
98. Sunakawa Y, Tsuji A, Fujii M, Ichikawa W. No benefit from the addition
of anti-EGFR antibody in all right-sided metastatic colorectal cancer? Ann
Oncol. (2017) 28:2030–1. doi: 10.1093/annonc/mdx231
99. Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, et al. Second-line
cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic
colorectal cancer with wild-type KRAS. Cancer Sci. (2013) 104:473–80.
doi: 10.1111/cas.12098
100. Carrato A, Gomez A, Escudero P, Chaves M, Rivera F, Marcuello E,
et al. Panitumumab and irinotecan every 3 weeks is an active and
convenient regimen for second-line treatment of patients with wild-type
K-RAS metastatic colorectal cancer. Clin Transl Oncol. (2013) 15:705–11.
doi: 10.1007/s12094-012-0993-x
101. Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, et al. Final
results and outcomes by prior bevacizumab exposure, skin toxicity, and
hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority
study of panitumumab versus cetuximab in chemorefractory wild-type
KRAS exon 2 metastatic colorectal cancer. Eur J Cancer. (2016) 68:51–9.
doi: 10.1016/j.ejca.2016.08.010
102. Sugimoto N, Sakai D, Tamura T, Hara H, Nishina T, Esaki T, et al.
Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-
11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-
type (WT)metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU),
CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G. J Clin Oncol. (2017)
35(suppl):661. doi: 10.1200/JCO.2017.35.4_suppl.661
103. Andre T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C,
et al. Panitumumab combined with irinotecan for patients with KRAS wild-
type metastatic colorectal cancer refractory to standard chemotherapy: a
GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol.
(2013) 24:412–9. doi: 10.1093/annonc/mds465
104. Nishi T, Hamamoto Y, Nagase M, Denda T, Yamaguchi K, Amagai K, et al.
Phase II trial of panitumumab with irinotecan as salvage therapy for patients
with advanced or recurrent colorectal cancer (TOPIC study). Oncol Lett.
(2016) 11:4049–54. doi: 10.3892/ol.2016.4532
105. Gil Delgado M, Spano JP, Khayat D. Cetuximab plus irinotecan in refractory
colorectal cancer patients. Expert Rev Anticancer Ther. (2007) 7:407–13.
doi: 10.1586/14737140.7.4.407
106. Lim R, Sun Y, Im SA, Hsieh RK, Yau TK, Bonaventura A, et al.
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer
patients: the ELSIE study. World J Gastroenterol. (2011) 17:1879–88.
doi: 10.3748/wjg.v17.i14.1879
107. Pantelic A, Markovic M, Pavlovic M, Jancic S. Cetuximab in third-line
therapy of patients with metastatic colorectal cancer: a single institution
experience. J BUON. (2016) 21:70–9.
108. Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J,
et al. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer
progressing on irinotecan: the LABEL study. Clin Colorectal Cancer. (2010)
9:282–9. doi: 10.3816/CCC.2010.n.041
109. Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet
Y, Gelderblom H, et al. Intrapatient cetuximab dose escalation in
metastatic colorectal cancer according to the grade of early skin
reactions: the randomized EVEREST study. J Clin Oncol. (2012) 30.
doi: 10.1200/JCO.2011.40.9243
110. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al.
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer
progressing on irinotecan: MABEL Study. J Clin Oncol. (2008) 26:5335–43.
doi: 10.1200/JCO.2008.16.3758
111. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D,
Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in
Advanced Colorectal Cancer. N Engl J Med. (2008) 359:1757–65.
doi: 10.1056/NEJMoa0804385
112. Sobrero AF, Lenz H-J, Eng C, Scheithauer W, Middleton GW, Chen W-F,
et al. Retrospective analysis of overall survival (OS) by subsequent therapy in
patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC)
receiving irinotecan ± cetuximab in the EPIC study. J Clin Oncol. (2019)
37(suppl):3580. doi: 10.1200/JCO.2019.37.15_suppl.3580
113. Modest D, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A,
Vehling-Kaiser U, et al. 2nd-line therapies after 1st-line therapy with
FOLFIRI in combination with cetuximab or bevacizumab in patients with
KRAS wild-type metastatic colorectal cancer (mCRC) - analysis of the
AIO KRK 0306 (FIRE 3) - trial. Ann Oncol. (2014) 25(suppl 2):0018.
doi: 10.1093/annonc/mdu193.18
114. Taniguchi H, Komori A, Narita Y, Kadowaki S, Ura T, Andoh M, et al.
A short interval between bevacizumab and anti-epithelial growth factor
receptor therapy interferes with efficacy of subsequent anti-EGFR therapy
Frontiers in Oncology | www.frontiersin.org 15 September 2019 | Volume 9 | Article 849
García-Foncillas et al. Two Distinct Anti-EGFRs: Cetuximab and Panitumumab
for refractory colorectal cancer. Jpn J Clin Oncol. (2016) 46:228–33.
doi: 10.1093/jjco/hyv193
115. Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, et al. A phase
II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for
Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol.
(2013) 43:1080–6. doi: 10.1093/jjco/hyt127
116. Nishina T, Taniguchi H, Sakai D, Kawakami H, Sugimoto N, Hara H, et al.
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G
study of panitumumab plus irinotecan versus cetuximab plus irinotecan
in chemorefractory metastatic colorectal cancer. J Clin Oncol. (2018)
36(suppl):624. doi: 10.1200/JCO.2018.36.4_suppl.624
117. Taniguchi H, Yamanaka T, Sakai D, Yamazaki K, Muro K, Peeters
M, et al. Panitumumab versus cetuximab in patients with wild-
type KRAS exon 2 metastatic colorectal cancer who received prior
bevacizumab therapy: a combined analysis of individual patient data
from ASPECCT and WJOG6510G. J Clin Oncol. (2018) 36(suppl):745.
doi: 10.1200/JCO.2018.36.4_suppl.745
118. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al.
Final results from PRIME: randomized phase III study of panitumumab with
FOLFOX4 for first-line treatment of metastatic colorectal cancer.Ann Oncol.
(2014) 25:1346–55. doi: 10.1093/annonc/mdu141
119. Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S, et al.
Different toxicity of cetuximab and panitumumab in metastatic colorectal
cancer treatment: a systematic review and meta-analysis. Oncology. (2018)
94:191–9. doi: 10.1159/000486338
120. Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, et al.
Platinum-induced neurotoxicity and preventive strategies: past, present, and
future. Oncologist. (2015) 20:411–32. doi: 10.1634/theoncologist.2014-0044
121. Teng CL, Wang CY, Chen YH, Lin CH, Hwang WL. Optimal sequence of
irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer:
a population-based observational study. PLoS ONE. (2015) 10:e0135673.
doi: 10.1371/journal.pone.0135673
122. NCCN Clinical Practice Guidelines in Oncology. Head and Neck
Cancers. V2.2017. Fort Washington, PA: National Comprehensive Cancer
Network (2017).
123. Gregoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO
Guidelines Working Group. Squamous cell carcinoma of the head and
neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. (2010) 21(Suppl 5):v184–6.
doi: 10.1093/annonc/mdq185
124. Giralt T, Trigo J, Nuyts S. A phase 2, randomized trial (CONCERT-2)
of panitumumab plus radiotherapy compared with chemoradiotherapy in
patients with unresected, locally advanced squamous cell carcinoma of the
head and neck. Lancet Oncol. (2014) 16:221-32. doi: 10.1016/S1470-2045(14)
71200-8
125. Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al.
Phase III randomized trial of standard fractionation radiotherapy (SFX)
with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy
(AFX) with panitumumab (PMab) in patients (pts) with locoregionally
advanced squamous cell carcinoma of the head and neck (LA-SCCHN):
NCIC Clinical Trials Group HN.6 trial. J Clin Oncol. (2015) 33(suppl):6000.
doi: 10.1200/jco.2015.33.15_suppl.6000
126. Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E,
Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab
in patients with recurrent or metastatic squamous-cell carcinoma of
the head and neck (SPECTRUM): an open-label phase 3 randomised
trial. Lancet Oncol. (2013) 14:697–710. doi: 10.1016/S1470-2045(13)
70181-5
127. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al.
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N
Engl J Med. (2008) 359:1116–27. doi: 10.1056/NEJMoa0802656
128. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and
neck. N Engl J Med. (2006) 354:567–78. doi: 10.1056/NEJMoa053422
129. Toh JW, de Souza P, Lim SH, Singh P, Chua W, Ng W, et al. The potential
value of immunotherapy in colorectal cancers: review of the evidence
for programmed death-1 inhibitor therapy. Clin Colorectal Cancer. (2016)
15:285–91. doi: 10.1016/j.clcc.2016.07.007
130. Liu X, Guo WJ, Zhang XW, Cai X, Tian S, Li J. Cetuximab enhances the
activities of irinotecan on gastric cancer cell lines through downregulating
the EGFR pathway upregulated by irinotecan. Cancer Chemother Pharmacol.
(2011) 68:871–8. doi: 10.1007/s00280-011-1559-2
131. Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy
in tumors of the gastrointestinal tract. Oncologist. (2008) 13:39–50.
doi: 10.1634/theoncologist.2006-0049
132. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G,
et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and
epidermal growth factor receptor inhibitors. Ann Oncol. (2005) 16(Suppl
4):iv61–8. doi: 10.1093/annonc/mdi910
133. Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, et al. Trial
watch: immunogenic cell death induction by anticancer chemotherapeutics.
Oncoimmunology. (2017) 6:e1386829. doi: 10.1080/2162402X.2017.1386829
134. Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer
T, Worah K, et al. Human CD1c(+) DCs are critical cellular mediators of
immune responses induced by immunogenic cell death. Oncoimmunology.
(2016) 5:e1192739. doi: 10.1080/2162402X.2016.1192739
135. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the
immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res.
(2014) 20:2831–7. doi: 10.1158/1078-0432.CCR-13-3141
136. Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F,
et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade
therapy. Immunity. (2016) 44:343–54. doi: 10.1016/j.immuni.2015.11.024
137. Wang W, Wu L, Zhang J, Wu H, Han E, Guo Q. Chemoimmunotherapy by
combining oxaliplatin with immune checkpoint blockades reduced tumor
burden in colorectal cancer animal model. Biochem Biophys Res Commun.
(2017) 487:1–7. doi: 10.1016/j.bbrc.2016.12.180
Conflict of Interest Statement: JG-F has had an advisory role and has received
honoraria for talks from Amgen, Bayer, Sanofi, Merck Healthcare KGaA, Roche,
Servier, Eli Lilly, Novartis, Pfizer, BMS, MSD, and AstraZeneca. YS has received
honoraria for talks from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult
Honsha, Takeda, Merck Serono, Bayer Yakuhin, and Sanofi. DA has had an
advisory role and has received honoraria fromMerck Healthcare KGaA, Teva, and
Bayer. ZW has received consultation fees and honoraria from EMD Serono, Lilly,
Genentech, and Novartis. PR and PW are employees of Merck Healthcare KGaA,
Darmstadt, Germany. SS has had an advisory role and has received honoraria for
talks from Amgen, Bayer, Eli Lilly, Merck Healthcare KGaA, Roche, Sanofi, and
Takeda.
Copyright © 2019 García-Foncillas, Sunakawa, Aderka, Wainberg, Ronga, Witzler
and Stintzing. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org 16 September 2019 | Volume 9 | Article 849
